Mutation of oncogene is common in non-small cell lung cancers (NSCLC), however, it is clinical significance continues to be controversial. 1.21-1.61 and 1.11-1.64). Although mutant individuals offered worse DFS and PFS of chemotherapy (HR=1.33 and 1.11, 95% CI 0.97-1.84 and 0.95-1.30), and reduce response price to EGFR-TKIs or chemotherapy (RR=0.55 and 0.88, 95 % CI… Continue reading Mutation of oncogene is common in non-small cell lung cancers (NSCLC),